This document discusses coronary artery disease in HIV patients. It covers the relative magnitude of cardiovascular disease among HIV patients, current data on the association between HIV and coronary artery disease, known risk factors and how they may be modulated by HIV diagnosis, screening and prevention recommendations, and areas for future research. Key points include increased rates of myocardial infarction and atherosclerosis in HIV patients, traditional and HIV-specific risk factors, screening tools and their limitations, effects of antiretroviral therapy on risk, and lifestyle and medical interventions for prevention.
This document discusses cardiovascular diseases in HIV patients. It notes that cardiovascular disease is more common in HIV patients due to multiple potential factors, including traditional risk factors, HIV itself, antiretroviral therapy, and chronic inflammation. It also discusses specific cardiac complications in more detail, such as cardiomyopathy, pericardial effusion, endocarditis, pulmonary hypertension, vasculitis, and the possible association between viral infections and coronary artery disease.
Cardiovascular abnormalities are common in 25-75% of AIDS patients, caused by either direct infection from HIV or indirect effects of antiretroviral therapy. Cardiovascular diseases are among the top 4 leading causes of death in AIDS patients. HIV attacks the immune system and can cause conditions like dilated cardiomyopathy, endocarditis, myocarditis, pericarditis, pulmonary hypertension, coronary artery disease, and atherosclerosis. Risk factors for cardiovascular problems in AIDS patients include malnutrition, opportunistic infections, autoimmunity, malignancy, lifestyle factors, and certain antiretroviral drugs which can cause metabolic abnormalities. Lifestyle modifications, lipid management, immunoglobulin therapy, surgery, and addressing nutritional deficiencies
1. HIV was first described in 1981 and is caused by HIV-1 and HIV-2 viruses which deplete CD4 lymphocytes. As of 2000, 58 million people were infected globally and 21.8 million had died.
2. Cardiac manifestations are common in HIV/AIDS patients, occurring in 28-73% of patients. Prior to antiretroviral therapy, cardiac disease was usually only detected at autopsy.
3. Guidelines recommend regular echocardiograms to monitor cardiac dysfunction in HIV patients, with increased frequency if abnormalities are detected. Endocarditis prevalence is increased in HIV patients.
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Hivlife Info
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
Anticoagulation in atrial fibrillationMashiul Alam
This document discusses anticoagulation for atrial fibrillation (AF). It covers the epidemiology and pathophysiology of AF, as well as the risks of stroke. It describes scoring systems like CHADS2 and CHA2DS2-VASc that are used to determine stroke risk and recommend antithrombotic therapy. Newer oral anticoagulants like apixaban, dabigatran and rivaroxaban are discussed and compared to warfarin. Guidelines for anticoagulation in various clinical scenarios involving AF are provided, such as with stable ischemic heart disease, intracoronary stents, acute coronary syndrome, and cardioversion.
This document discusses heart failure, including its increasing prevalence globally, definitions, classifications, management, and new strategies. Some key points:
- Heart failure prevalence is increasing worldwide and mortality remains high, around 50% within 5 years of diagnosis.
- The universal definition characterizes heart failure as a clinical syndrome caused by structural or functional cardiac abnormalities, accompanied by typical symptoms and signs.
- Management focuses on guideline-directed medical therapies (GDMT) including ACE inhibitors, ARBs, beta-blockers, and MRAs, though utilization remains suboptimal.
- The PARADIGM-HF trial showed the ARNI drug sacubitril/valsartan reduced cardiovascular death and heart failure
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEFDuke Heart
1) Initiating all four guideline directed medical therapies (GDMT) simultaneously or in rapid sequence for heart failure with reduced ejection fraction (HFrEF) provides early clinical benefits by reducing mortality and hospitalization within weeks.
2) Starting medications together enables better tolerance as therapies help patients tolerate side effects of each other. Delaying any medication needlessly increases risks.
3) There is no evidence that simultaneous initiation increases intolerance, and initiating at low doses with up-titration mitigates risks. Not starting medications exposes patients to worsening health outcomes.
Primary Prevention Of Sudden Cardiac Death - Role Of DevicesArindam Pande
ICD is most cost‑effective when used for patients at high‑risk of arrhythmic death and low‑risk of other causes of death.
Specific patient populations are now recognized for whom the benefit of ICD therapy outweighs any risks
Categorizing patients on the basis of only LVEF and NYHA Functional Class can aid in identification of patients who have highest benefit from primary preventions
This document discusses cardiovascular diseases in HIV patients. It notes that cardiovascular disease is more common in HIV patients due to multiple potential factors, including traditional risk factors, HIV itself, antiretroviral therapy, and chronic inflammation. It also discusses specific cardiac complications in more detail, such as cardiomyopathy, pericardial effusion, endocarditis, pulmonary hypertension, vasculitis, and the possible association between viral infections and coronary artery disease.
Cardiovascular abnormalities are common in 25-75% of AIDS patients, caused by either direct infection from HIV or indirect effects of antiretroviral therapy. Cardiovascular diseases are among the top 4 leading causes of death in AIDS patients. HIV attacks the immune system and can cause conditions like dilated cardiomyopathy, endocarditis, myocarditis, pericarditis, pulmonary hypertension, coronary artery disease, and atherosclerosis. Risk factors for cardiovascular problems in AIDS patients include malnutrition, opportunistic infections, autoimmunity, malignancy, lifestyle factors, and certain antiretroviral drugs which can cause metabolic abnormalities. Lifestyle modifications, lipid management, immunoglobulin therapy, surgery, and addressing nutritional deficiencies
1. HIV was first described in 1981 and is caused by HIV-1 and HIV-2 viruses which deplete CD4 lymphocytes. As of 2000, 58 million people were infected globally and 21.8 million had died.
2. Cardiac manifestations are common in HIV/AIDS patients, occurring in 28-73% of patients. Prior to antiretroviral therapy, cardiac disease was usually only detected at autopsy.
3. Guidelines recommend regular echocardiograms to monitor cardiac dysfunction in HIV patients, with increased frequency if abnormalities are detected. Endocarditis prevalence is increased in HIV patients.
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Hivlife Info
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
Anticoagulation in atrial fibrillationMashiul Alam
This document discusses anticoagulation for atrial fibrillation (AF). It covers the epidemiology and pathophysiology of AF, as well as the risks of stroke. It describes scoring systems like CHADS2 and CHA2DS2-VASc that are used to determine stroke risk and recommend antithrombotic therapy. Newer oral anticoagulants like apixaban, dabigatran and rivaroxaban are discussed and compared to warfarin. Guidelines for anticoagulation in various clinical scenarios involving AF are provided, such as with stable ischemic heart disease, intracoronary stents, acute coronary syndrome, and cardioversion.
This document discusses heart failure, including its increasing prevalence globally, definitions, classifications, management, and new strategies. Some key points:
- Heart failure prevalence is increasing worldwide and mortality remains high, around 50% within 5 years of diagnosis.
- The universal definition characterizes heart failure as a clinical syndrome caused by structural or functional cardiac abnormalities, accompanied by typical symptoms and signs.
- Management focuses on guideline-directed medical therapies (GDMT) including ACE inhibitors, ARBs, beta-blockers, and MRAs, though utilization remains suboptimal.
- The PARADIGM-HF trial showed the ARNI drug sacubitril/valsartan reduced cardiovascular death and heart failure
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEFDuke Heart
1) Initiating all four guideline directed medical therapies (GDMT) simultaneously or in rapid sequence for heart failure with reduced ejection fraction (HFrEF) provides early clinical benefits by reducing mortality and hospitalization within weeks.
2) Starting medications together enables better tolerance as therapies help patients tolerate side effects of each other. Delaying any medication needlessly increases risks.
3) There is no evidence that simultaneous initiation increases intolerance, and initiating at low doses with up-titration mitigates risks. Not starting medications exposes patients to worsening health outcomes.
Primary Prevention Of Sudden Cardiac Death - Role Of DevicesArindam Pande
ICD is most cost‑effective when used for patients at high‑risk of arrhythmic death and low‑risk of other causes of death.
Specific patient populations are now recognized for whom the benefit of ICD therapy outweighs any risks
Categorizing patients on the basis of only LVEF and NYHA Functional Class can aid in identification of patients who have highest benefit from primary preventions
This document discusses strategies to minimize right ventricular pacing, which can have deleterious effects. It summarizes several clinical trials that evaluated ventricular versus atrial or dual-chamber pacing. The trials generally found that atrial or dual-chamber pacing reduced atrial fibrillation compared to ventricular pacing, though effects on other outcomes like mortality were less clear. The document recommends that right ventricular pacing be avoided or minimized when possible, through use of AAI pacing, DDD pacing with long fixed AV delays, search AV hysteresis algorithms, or mode-switching algorithms that favor intrinsic conduction.
Anticoagulation therapy for atrial fibrillationLyndon Woytuck
The patient, a 73-year-old man with atrial fibrillation, hypertension, and diabetes, presented with symptoms of a transient ischemic attack (TIA). Tests ruled out bleeding and the patient was diagnosed with a TIA. He was prescribed warfarin and had his international normalized ratio monitored and maintained between 2-3 to prevent further strokes, and did not experience another TIA in the following year.
This document provides an overview of echocardiographic evaluation of restrictive cardiomyopathy. Key points include:
- Restrictive cardiomyopathy is characterized by a nondilated left ventricle with abnormal diastolic function and typically normal systolic function.
- Causes include infiltrative diseases like amyloidosis and storage diseases. Echocardiography can help diagnose but it is more difficult than other cardiomyopathies.
- Findings include low diastolic volume, normal ejection fraction, diastolic dysfunction with rapid early mitral inflow. Echocardiography helps differentiate restrictive cardiomyopathy from constrictive pericarditis.
Atrial fibrillation is the most common cardiac arrhythmia. It is characterized by irregular heart rhythms without distinct P waves due to irregular activation of the atria. The prevalence increases with age and is higher in men. Risk factors include hypertension, heart disease, heart failure, thyroid disorders, obesity, and lung disease. If left untreated, atrial fibrillation can lead to stroke, heart failure, reduced quality of life, and death. The pathogenesis involves multiple activation wavelets in the atria which causes the muscle to shorten its refractory period, making further arrhythmias more likely. Atrial fibrillation is classified based on its pattern and duration.
The document provides an overview of basic ICD treatment and concepts, including the evolution of ICDs, device components, automated functions such as sensing, detection, and SVT discrimination, and troubleshooting. Key aspects of ICD systems like battery depletion, lead design, and programming are discussed at a high level.
The document discusses World Hypertension Day, which is observed annually on May 17th to raise awareness about hypertension. It provides information on understanding hypertension, including risk factors and health implications. The presentation's objectives are to raise awareness, promote prevention, encourage collaboration, share resources, and inspire action to address the growing issue of hypertension worldwide.
This document summarizes several key trials that evaluated percutaneous coronary intervention (PCI) versus optimal medical therapy (OMT) in patients with stable coronary artery disease. The COURAGE and BARI 2D trials found no difference in mortality or cardiovascular outcomes between PCI plus OMT versus OMT alone. The FAME 2 trial found lower rates of urgent revascularization with FFR-guided PCI plus OMT versus OMT alone. Overall, OMT should be the first-line treatment for stable angina, with PCI reserved for refractory angina or markedly positive stress tests. More research is still needed to define the role of PCI versus OMT.
The SPRINT trial studied over 9,000 patients at high risk for cardiovascular events to compare intensive blood pressure control (target <120 mm Hg systolic) to standard control (target <140 mm Hg). It found that intensive control significantly reduced rates of fatal and nonfatal heart attacks, heart failure, and death from any cause. However, intensive control also increased some adverse effects like acute kidney injury and hypotension. Overall, the trial demonstrated benefits of very tight blood pressure control for high-risk patients without diabetes.
This document outlines an introduction to pulmonary hypertension including its epidemiology, etiology, pathogenesis, clinical features, treatment, and future directions. It defines pulmonary hypertension and notes the most common causes are lung diseases like COPD. In Nigeria, common causes include COPD, tuberculosis, connective tissue diseases, and sickle cell disease. The pathogenesis involves remodeling of the pulmonary vasculature from factors like endothelial dysfunction and an imbalance of vasoconstrictors and vasodilators. Over time, this can lead to right heart failure if the right ventricle can no longer compensate for the increased resistance.
Stroke prevention in patients with atrial fibrillationMgfamiliar Net
This document summarizes a webinar on stroke prevention in patients with atrial fibrillation. It reviews the evidence for using novel oral anticoagulants (NOACs), provides a clinical guide on how to use NOACs in practice, and discusses strategies to reduce ischemic and bleeding risks using real-world cases. The document also includes a quiz on the clinical use of NOACs and summarizes key advantages of NOACs over warfarin. Real-world cases demonstrate the impact of NOAC introduction on optimizing anticoagulation and reducing strokes in atrial fibrillation patients.
This document contains information about hypertrophic obstructive cardiomyopathy (HOCM). It begins with an overview of HOCM, defining it as a genetic heart condition characterized by asymmetric left ventricular hypertrophy. It then discusses the pathophysiology of HOCM, focusing on left ventricular outflow tract obstruction, diastolic dysfunction, myocardial ischemia, and mitral regurgitation due to systolic anterior motion of the mitral valve. The document outlines clinical manifestations such as symptoms, physical exam findings, ECG and echocardiographic features, and complications. It concludes by covering treatment options for HOCM including medications, surgical septal myectomy via transaortic or transapical approaches, and other procedures like alcohol septal
1. Low flow aortic stenosis can be caused by either low or normal ejection fraction and is an important entity that is often underdiagnosed.
2. Evaluation of low flow AS involves calculating aortic valve area using continuity equation in addition to gradients, as well as tests like dobutamine stress echocardiogram, CT calcium scoring, and novel markers of left ventricular function.
3. Treatment depends on symptom status and severity of stenosis, with aortic valve replacement generally recommended for symptomatic patients or asymptomatic patients with low ejection fraction, even in the presence of low flow and gradients.
ACUTE CORONARY SYNDROME FOR CRITICAL CAREAbhinovKandur
The document defines acute coronary syndrome (ACS) as a group of diseases including unstable angina, myocardial infarction, and sudden cardiac death. ACS is classified into STEMI, NSTEMI, or unstable angina based on ECG and cardiac biomarker findings. The diagnosis of ACS involves taking a medical history, performing an ECG, and measuring cardiac biomarkers like troponin and CK-MB. Treatment involves pain relief medications, antiplatelet drugs, anticoagulants, and sometimes revascularization through procedures like angioplasty.
This document discusses cardiac sarcoidosis, which can present with vague symptoms like syncope, palpitations, or heart failure. Genetic factors may increase risk. Screening tests lack sensitivity and specificity. Complications include conduction abnormalities, arrhythmias like atrial fibrillation, and heart failure. Treatment involves immunosuppression with steroids. Prognosis depends on left ventricular function, with poorer outcomes when EF is below 30%.
This document provides an overview of hypertrophic cardiomyopathy (HCM). It begins with definitions of cardiomyopathy and HCM. It then discusses the historical perspective, genetic basis, morphology, pathophysiology, clinical features, diagnosis, and management of HCM. Some key points include:
- HCM is a genetic heart condition characterized by unexplained thickening of the heart muscle. It is the most common cause of sudden cardiac death in young people.
- The genetic basis involves mutations in genes encoding sarcomere proteins. This leads to impaired relaxation and increased calcium sensitivity of the heart muscle.
- Morphologically, HCM involves asymmetric left ventricular hypertrophy and abnormalities of the mitral valve apparatus. Hist
HIV treatment has improved and patients can expect life expectancy close to that of HIV negatives. Smoking cessation is therefore an intervention that must be adequately addressed in this population
The presentation discussed how inflammation persists even during HIV therapy and may contribute to non-AIDS related health issues in HIV patients. It reviewed evidence that low-level viremia, microbial translocation, and viral co-infections can drive inflammation. Early ART, ART intensification, statins, diet, exercise, and steroids may help reduce inflammation, but more research is needed on interventions targeting the underlying causes of persistent inflammation during HIV therapy.
This document discusses strategies to minimize right ventricular pacing, which can have deleterious effects. It summarizes several clinical trials that evaluated ventricular versus atrial or dual-chamber pacing. The trials generally found that atrial or dual-chamber pacing reduced atrial fibrillation compared to ventricular pacing, though effects on other outcomes like mortality were less clear. The document recommends that right ventricular pacing be avoided or minimized when possible, through use of AAI pacing, DDD pacing with long fixed AV delays, search AV hysteresis algorithms, or mode-switching algorithms that favor intrinsic conduction.
Anticoagulation therapy for atrial fibrillationLyndon Woytuck
The patient, a 73-year-old man with atrial fibrillation, hypertension, and diabetes, presented with symptoms of a transient ischemic attack (TIA). Tests ruled out bleeding and the patient was diagnosed with a TIA. He was prescribed warfarin and had his international normalized ratio monitored and maintained between 2-3 to prevent further strokes, and did not experience another TIA in the following year.
This document provides an overview of echocardiographic evaluation of restrictive cardiomyopathy. Key points include:
- Restrictive cardiomyopathy is characterized by a nondilated left ventricle with abnormal diastolic function and typically normal systolic function.
- Causes include infiltrative diseases like amyloidosis and storage diseases. Echocardiography can help diagnose but it is more difficult than other cardiomyopathies.
- Findings include low diastolic volume, normal ejection fraction, diastolic dysfunction with rapid early mitral inflow. Echocardiography helps differentiate restrictive cardiomyopathy from constrictive pericarditis.
Atrial fibrillation is the most common cardiac arrhythmia. It is characterized by irregular heart rhythms without distinct P waves due to irregular activation of the atria. The prevalence increases with age and is higher in men. Risk factors include hypertension, heart disease, heart failure, thyroid disorders, obesity, and lung disease. If left untreated, atrial fibrillation can lead to stroke, heart failure, reduced quality of life, and death. The pathogenesis involves multiple activation wavelets in the atria which causes the muscle to shorten its refractory period, making further arrhythmias more likely. Atrial fibrillation is classified based on its pattern and duration.
The document provides an overview of basic ICD treatment and concepts, including the evolution of ICDs, device components, automated functions such as sensing, detection, and SVT discrimination, and troubleshooting. Key aspects of ICD systems like battery depletion, lead design, and programming are discussed at a high level.
The document discusses World Hypertension Day, which is observed annually on May 17th to raise awareness about hypertension. It provides information on understanding hypertension, including risk factors and health implications. The presentation's objectives are to raise awareness, promote prevention, encourage collaboration, share resources, and inspire action to address the growing issue of hypertension worldwide.
This document summarizes several key trials that evaluated percutaneous coronary intervention (PCI) versus optimal medical therapy (OMT) in patients with stable coronary artery disease. The COURAGE and BARI 2D trials found no difference in mortality or cardiovascular outcomes between PCI plus OMT versus OMT alone. The FAME 2 trial found lower rates of urgent revascularization with FFR-guided PCI plus OMT versus OMT alone. Overall, OMT should be the first-line treatment for stable angina, with PCI reserved for refractory angina or markedly positive stress tests. More research is still needed to define the role of PCI versus OMT.
The SPRINT trial studied over 9,000 patients at high risk for cardiovascular events to compare intensive blood pressure control (target <120 mm Hg systolic) to standard control (target <140 mm Hg). It found that intensive control significantly reduced rates of fatal and nonfatal heart attacks, heart failure, and death from any cause. However, intensive control also increased some adverse effects like acute kidney injury and hypotension. Overall, the trial demonstrated benefits of very tight blood pressure control for high-risk patients without diabetes.
This document outlines an introduction to pulmonary hypertension including its epidemiology, etiology, pathogenesis, clinical features, treatment, and future directions. It defines pulmonary hypertension and notes the most common causes are lung diseases like COPD. In Nigeria, common causes include COPD, tuberculosis, connective tissue diseases, and sickle cell disease. The pathogenesis involves remodeling of the pulmonary vasculature from factors like endothelial dysfunction and an imbalance of vasoconstrictors and vasodilators. Over time, this can lead to right heart failure if the right ventricle can no longer compensate for the increased resistance.
Stroke prevention in patients with atrial fibrillationMgfamiliar Net
This document summarizes a webinar on stroke prevention in patients with atrial fibrillation. It reviews the evidence for using novel oral anticoagulants (NOACs), provides a clinical guide on how to use NOACs in practice, and discusses strategies to reduce ischemic and bleeding risks using real-world cases. The document also includes a quiz on the clinical use of NOACs and summarizes key advantages of NOACs over warfarin. Real-world cases demonstrate the impact of NOAC introduction on optimizing anticoagulation and reducing strokes in atrial fibrillation patients.
This document contains information about hypertrophic obstructive cardiomyopathy (HOCM). It begins with an overview of HOCM, defining it as a genetic heart condition characterized by asymmetric left ventricular hypertrophy. It then discusses the pathophysiology of HOCM, focusing on left ventricular outflow tract obstruction, diastolic dysfunction, myocardial ischemia, and mitral regurgitation due to systolic anterior motion of the mitral valve. The document outlines clinical manifestations such as symptoms, physical exam findings, ECG and echocardiographic features, and complications. It concludes by covering treatment options for HOCM including medications, surgical septal myectomy via transaortic or transapical approaches, and other procedures like alcohol septal
1. Low flow aortic stenosis can be caused by either low or normal ejection fraction and is an important entity that is often underdiagnosed.
2. Evaluation of low flow AS involves calculating aortic valve area using continuity equation in addition to gradients, as well as tests like dobutamine stress echocardiogram, CT calcium scoring, and novel markers of left ventricular function.
3. Treatment depends on symptom status and severity of stenosis, with aortic valve replacement generally recommended for symptomatic patients or asymptomatic patients with low ejection fraction, even in the presence of low flow and gradients.
ACUTE CORONARY SYNDROME FOR CRITICAL CAREAbhinovKandur
The document defines acute coronary syndrome (ACS) as a group of diseases including unstable angina, myocardial infarction, and sudden cardiac death. ACS is classified into STEMI, NSTEMI, or unstable angina based on ECG and cardiac biomarker findings. The diagnosis of ACS involves taking a medical history, performing an ECG, and measuring cardiac biomarkers like troponin and CK-MB. Treatment involves pain relief medications, antiplatelet drugs, anticoagulants, and sometimes revascularization through procedures like angioplasty.
This document discusses cardiac sarcoidosis, which can present with vague symptoms like syncope, palpitations, or heart failure. Genetic factors may increase risk. Screening tests lack sensitivity and specificity. Complications include conduction abnormalities, arrhythmias like atrial fibrillation, and heart failure. Treatment involves immunosuppression with steroids. Prognosis depends on left ventricular function, with poorer outcomes when EF is below 30%.
This document provides an overview of hypertrophic cardiomyopathy (HCM). It begins with definitions of cardiomyopathy and HCM. It then discusses the historical perspective, genetic basis, morphology, pathophysiology, clinical features, diagnosis, and management of HCM. Some key points include:
- HCM is a genetic heart condition characterized by unexplained thickening of the heart muscle. It is the most common cause of sudden cardiac death in young people.
- The genetic basis involves mutations in genes encoding sarcomere proteins. This leads to impaired relaxation and increased calcium sensitivity of the heart muscle.
- Morphologically, HCM involves asymmetric left ventricular hypertrophy and abnormalities of the mitral valve apparatus. Hist
HIV treatment has improved and patients can expect life expectancy close to that of HIV negatives. Smoking cessation is therefore an intervention that must be adequately addressed in this population
The presentation discussed how inflammation persists even during HIV therapy and may contribute to non-AIDS related health issues in HIV patients. It reviewed evidence that low-level viremia, microbial translocation, and viral co-infections can drive inflammation. Early ART, ART intensification, statins, diet, exercise, and steroids may help reduce inflammation, but more research is needed on interventions targeting the underlying causes of persistent inflammation during HIV therapy.
The document discusses cardiovascular risk in HIV patients. It finds that HIV patients have approximately double the risk of heart attacks and myocardial infarction compared to HIV-negative people after adjusting for traditional risk factors. Interrupting antiretroviral therapy, as shown in the SMART study, increases the risk of opportunistic disease, death, and non-AIDS events like cardiovascular or renal disease compared to continuous treatment. Protease inhibitors have been associated with a slightly higher risk of heart attacks than non-nucleoside reverse transcriptase inhibitors.
HIV infection is increasingly affecting older individuals as treatment allows for longer lifespans. Older adults with HIV have higher rates of age-related comorbidities like cardiovascular disease, cancer, liver disease, kidney disease, lung disease, and bone disease than HIV-negative individuals of the same age. Management of these conditions in HIV requires screening for comorbidities, treating underlying viral infections, modifying lifestyle factors, and following guidelines for prevention and treatment of common age-related diseases.
ВИЧ-инфекция, воспаление и метаболические нарушения-связь с сердечно-сосудист...hivlifeinfo
HIV infection can increase the risk of cardiovascular disease through several mechanisms:
1. Chronic immune activation and inflammation caused by HIV and bacterial translocation damage blood vessels and increase the risk of atherosclerosis.
2. Persistent immune activation is associated with increased levels of endothelial adhesion molecules and inflammatory cytokines like IL-6 that further promote atherosclerosis.
3. Interleukin-18, which is elevated in HIV infection, may accelerate atherosclerosis through multiple pathways and also impair heart function.
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...hivlifeinfo
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It. 2015
In this downloadable slideset, Priscilla Y. Hsue, MD, and David A. Wohl, MD, discuss data on using traditional and newer markers and modalities to predict and prevent cardiovascular disease in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 3.21 MB
Date posted: 7/16/2015
Managing CV risk in Inflammatory Arthritis (Focusing on Gout)Sidney Erwin Manahan
Presentation made during the 1st Inter-Hospital Rheumatology Fellows' Case Discussion on 9 June 2018 at the Speaker Feliciano Belmonte Auditorium, 7/F East Avenue Medical Center. Presentation highlights the needs to recognize gout as one of the rheumatic conditions that put patients at risk for developing CV disease.
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
This document discusses the potential link between periodontal disease and cardiovascular disease. It reviews evidence that periodontal disease is associated with increased risk of cardiovascular events like heart attack and stroke. The evidence includes observational studies showing associations between worse periodontal disease measures and higher levels of inflammatory biomarkers linked to cardiovascular risk. Experimental criteria for causality are examined, including strength of association, consistency across studies, biological plausibility via inflammation pathways, and dose-response relationships between periodontal disease severity and cardiovascular outcomes. While the link between the two conditions requires more research, current evidence suggests periodontal disease may increase risk of cardiovascular disease through inflammation.
This document discusses sepsis, systemic inflammatory response syndrome (SIRS), and multiple organ dysfunction syndrome (MODS). It defines sepsis as the body's systemic response to infection, SIRS as the inflammatory response to various insults, and MODS as altered organ function requiring intervention to maintain homeostasis. The relationship between these conditions is explained, with sepsis and SIRS often leading to MODS if not properly treated. Risk factors, pathogenesis, clinical manifestations, diagnosis, and collaborative management are outlined. Nursing interventions focus on preventing and treating infection, maintaining tissue oxygenation, and meeting nutritional and metabolic needs.
This document summarizes a presentation on immune activation in treated HIV infection. The presentation discusses how immune activation persists even during antiretroviral therapy (ART), contributing to increased risk of age-related diseases. It reviews evidence that microbial translocation, co-infections like CMV, and tryptophan catabolism via the kynurenine pathway may drive residual immune activation and inflammation during ART. Interventions like earlier ART initiation, statins, aspirin, exercise, and anti-CMV therapy may help reduce inflammation, but more research is still needed.
- There are two arboviruses, Chikungunya virus (CHIKV) and Zika virus (ZIKV), that have attracted interest in recent years due to increasing incidence and geographical range.
- CHIKV infection can cause long-term joint pain and arthritis in around 50% of cases. ZIKV is associated with Guillain-Barré syndrome in a small percentage of cases.
- A study of 29 patients with Guillain-Barré syndrome and recent ZIKV infection found clinical features similar to other causes of Guillain-Barré syndrome. Around 40% had anti-ganglioside antibodies. The incidence of Guillain-Barré
Cardiomyopathy in HIV patients has been shown to progress faster than idiopathic Dilated Cardiomyopathy in the HIV negative population. It is therefore important to recognize this condition early in this population and manage it appropriately. Studies need to be done to validate the current therapy for cardiomyopathy in this population since it is still unclear that LV dysfunction in this population responds in a similar fashion as in HIV negative patients with Dilated Cardiomyopathy
* Watch the video at the end of the presentation
Viral infections remain among the most important challenges in the management of the transplant recipient. This observation reflects both a predisposition to viral infection by immunosuppression that targets T-cell function, the diverse population of viruses, and the impact of viruses including infection, graft rejection, and malignancies. Traditionally, the manifestations of cytomegalovirus (CMV) infection have been termed “direct” (organ-specific) and “indirect” (immune) effects. More accurate terms might be “viral cytopathic” effects and “cellular and systemic immunologic” effects. The clinical manifestations of viral CMV infections are the result of suppression of multiple host defense mechanisms, predisposing to secondary invasion by such pathogens as P. jiroveci, Candida and Aspergillus species and increasing the risk for graft loss and death. As the biology of viral infection is explored, many of these manifestations of viral infection appear to be mediated not only by T-cells but also by the innate immune system.
This document summarizes research on genetic and environmental risk factors for multiple sclerosis (MS). It finds that MS is influenced by both hereditary and non-hereditary factors. Major genetic risk factors identified include the HLA-DRB1*1501 locus, the interleukin 7 receptor gene, and the interleukin 2 receptor gene, which together account for about 50% of MS's hereditability. Environmental factors associated with increased risk include Epstein-Barr virus, human herpesvirus 6, low vitamin D levels, and smoking.
The document summarizes the risks associated with surgical bleeding and blood transfusions. It discusses how bleeding can lead to hypovolemia and anemia, and the compensatory mechanisms the body employs. It then outlines the risks of transfusions, including transfusion reactions, infections transmitted through blood-borne pathogens, transfusion-related immune modulation that can increase infection risk and mortality, and the storage effects on red blood cells that are associated with increased morbidity and mortality. It notes that leukoreduction of blood products reduces some of these transfusion risks.
This study examined the relationship between atypical lymphocytes, large immature cells, platelet counts, and hematocrit in 79 patients with dengue virus infection. The results showed that increases in the percentage of atypical lymphocytes were associated with decreases in platelet count, suggesting atypical lymphocytes may play a role in platelet count fluctuations in dengue. A similar relationship was found between large immature cells and platelet count. The study supports the potential of atypical lymphocytes and large immature cells as predictive markers of the hematological changes seen in dengue, such as low platelet counts and increased hematocrit. However, limitations include the retrospective single-center design and lack of effective prognostic markers for vascular leakage in dengue.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
2. Educational Objectives
Relative Magnitude of CVS disease among HIV patients
Discuss current data on association between HIV and
Coronary Artery Disease
Current known cardiovascular disease risk factors and
how they may be modulated by HIV Dx
Evaluation and Screening of HIV patients for CVS disease
Prevention of Coronary Artery Disease in this population
Areas of Future Research
3. Underlying Causes of Death Among
Patients with a HIV Diagnosis
AIDS-defining events (27% vrs 36% in 2005, 47% in 2000)
Non-AIDS-defining and non-hepatitis-related cancers
(24% vrs 17% in 2005 and 11% in 2000)
Liver diseases (11%, 38% being hepatocellular
carcinoma)
Cardiovascular diseases (11%)
Other Infections (10%, 50% of the respiratory tract)
Suicide (5%)
All Cancer types (37%)
PhiliipeMorlat et al Paper #1130 - CROI 2012
8. Epidemiology of Atherosclerosis in
HIV
Myocardial Infarction Rates are 1.5 - 2 times higher
among HIV positive individuals
Incidence rate is about 11.13 per 1000 person yrs vrs
6.98 per 1000 person yrs in HIV negatives
Relative Risk based on data from a large Health System
in Massachusetts – 1.75 ( CI – 1.51 – 2.02; P < 0.0001)
Relative Risk appears to be higher in women than for
men – 2.98 ( CI – 2.33 – 3.75); P < 0.0001) compared to
1.40 (CI – 1.16 – 1.67; P <0.0003) for men
1. J Acquir Immune DeficSyndr. 2003;33:506 –512.
2. J Clin Endocrinology Metab, 2007, 92: 2506 – 2512
9. Epidemiology contd.
In a Case Control study HIV positive patient were
more likely to have 3 vessel disease compared to HIV
negatives 76% vrs 30%1
DAD Study data suggests an RR of 1.26 per year of ART
therapy (CI – 1.12 – 1.41; P < 0.001)2
The Relative Risk for MI in HIV positive patients 18 –
24 yrs – Ranges between 2.16 – 6.763
A study using data from the Danish HIV Cohort
revealed an increase in risk of MI in first 90 days after
initiating HAART RR – 7.44 (CI – 3.35 – 16.5)4
1. Arch Intern Med. 2003; 163(4): 457 – 460
2. N Engl J Med. 2003; 349: 1993 – 2003
3. J Acquir Immune DeficSyndr. 2003; 33:506-512
4. Clin Infect Dis. 2007; 44:1625-31
10. Incidents Rates of MI Across Cohorts and Databases
Circulation 2008; 118: e29 – e35
13. RISK FACTORS OF CVS DISEASE IN
HIV PATIENTS
Traditional risk factors; age, family history, male sex,
diabetes, hypertension, hyperlipidemia, smoking, obesity
CD4 count of < 200 after > 24mths of stable ART (RR - 1.66
CI – 1.14 – 1.85)3
High level viremia ( RR- 1.37, CI 1.04 – 1.81)1, 2
Duration of Protease Inhibitors therapy ( RR- 1.16 CI -1.10 –
1.23)2
Lipodystrophy or body fat redistrubution4
Micro-albuminuria5
1. N Engl J Med 2006; 355:2283 – 2296
2. N Engl J Med 2007;356:1723-1735
3. AIDS 2012; 26 (4) 465 - 474
4. J Acquir Immune DeficSyndr 2005; 39:44-54)
5. Nephrol. Dial. Transplant. 2008; 23 (10) : 3130 -3137
14. RISK FACTORS & MARKERS OF ELEVATED RISK
Contd
Coronary Artery Calcium1
Vitamin D deficiency2
Carotid Artery Intimal Medial Thickness3
C-Reactive Protein/high sensitivity CRP2
Soluble Tumor Necrosis Factor α Receptor 1
(sTNFα1)2
1. Fitch K, Abbara S, Lee H et al, AIDS 2012, 26:587–597
2. Legeai L, Vigourox C, Souberbiele JC et al; paper 883 CROI 2012
3. AIDS 2009, 23:1841–1849
15. Long-term complications in patients with poor
immunologic outcomes on suppressed ART
Dutch ATHENA cohort.
AIDS. 26(4):465-474, February 20, 2012.
DOI: 10.1097/QAD.0b013e32834f32f8
16. Impact of HAART Therapy on CVS Risk
Circulation 2008; 118: e29 – e35
17. Effects of ART therapy on Lipids
J Acquir Immune DeficSyndr 2009, 50: 54 -64
19. Atherogenesis in HIV
T-Cell activation
Cytokine dysregulation causing dyslipidemia
Metabolic effects of HIV therapy (insulin resistance)
Increased visceral adiposity
Inflammatory effects of HIV related Opportunistic
Infections
Increased proliferation of smooth muscle cells in the
intima
The Journal of Infectious Diseases 2012;205:S368–74
20. CARDIOVASCULAR DISEASE IN HIV
HIV Viral
Replication
Anti-
retroviral
Immune
Therapy
activation
Insulin
Inflammation
Resistance &
Diabetes
Macrophage Dyslipidemia
Recruitment
Atherosclerosis
Endothelial
Dysfunction
Hypertensio Genetics
Smoking
n
Modified from: Currier J.S., Topics in HIV Medicine, 2009, 17(3); 98-103
22. Relative increase in Risk of Cardiovascular Disease
By Different Risk Factors among HIV Patients
4
3.5
3
2.5
2
1.5
1
0.5
0
Increase in Risk of Cadiovascular Disease
The DAD Study Group. N Engl J Med 2007; 356:1723 - 1735
23. Relationship between Cardiovascular Risk Factors and the Rate of
Myocardial Infarction in HIV Patients
Cardiovascular Risk Relative Risk of Heart p-value
Factor Attack
Protease Inhibitor use per 1.10 (1.04 – 1.18) 0.002
additional year
Age per additional 5 yrs 1.32 ( 1.23 – 1.41) < 0.001
BMI > 30 1.34 (0.86 – 2.09) 0.19
Family History of Heart Dx 1.40 (0.92 – 1.91) 0.08
Current Smoker 2.92 (2.04 – 4.18) < 0.001
Former Smoker 1.63 (1.07 – 2.48) 0.02
Previous CVS event 4.64 (3.22 – 6.69) < 0.001
Diabetes 1.86 (1.31 – 2.65) < 0.001
Hypertension 1.30 (0.99 – 1.72) 0.06
Total Cholesterol per mmol 1.26 (1.19 – 1.35) < 0.001
HDL per mmol 0.65 (0.48 -0.88) 0.05
The DAD Study Group. N Engl J Med 2007;356:1723-1735
26. Framingham Risk
This is useful in HIV infected patients but may
underestimate CAD risk1,2
Does not include information on lipodystrophy currently
identified to be independently associated with CAD risk
The is no accounting for PI exposure suggested to
increase risk from 11-16 % per year of exposure
No consideration for poor immunologic response on
HAART Therapy another marker of likelihood of CAD
event
Does not include CD4 nadir
1. J Acquir Immune DeficSyndr 2009; 52 (2) 303 -304
2. HIV Medicine (2010) 11, 225 -231
3. Eur J PrevCardiol. 2012 Jun 20
27. Correlation between Framingham, DAD
and SCORE with cIMT
Villar S. et al 2012, European Journal of Preventive Cardiology, Epubahed of print.
28. Adding HIV Related Variables to
the D.A.D risk Equation
Villar S. et al 2012, European Journal of Preventive Cardiology, Epubahed of print.
29. Modified Framingham for HIV
Framingham Risk Calculator
The DAD Five Year Risk Equation
Source: Copenhagen HIV Program,
http://www.chip.dk/TOOLS/tabid/282/Default.aspx Acessed: 6/18/2012
30. Interventions
Early ART therapy
Careful choice of ART regimen
Lifestyle modification and diet
Smoking Cessation
Metformin therapy for those with insulin resistance
or evidence of metabolic syndrome
Statin Therapy
Vitamin D supplementation
32. Metabolic Effects of Metformin in HIV
Patients
Int. J ClinPract. 2007; 60 (3) 463 - 472
33. Statin Therapy
Statins lower lower LDL and hsCRP and TNFα in HIV
patients1,3
Statins lower lower hsCRP and TNFα in HIV patients1
Statin use reduced mortality by 67% in suppressed
patients 2
Statins may reverse PI mediated premature vascular
senescence in HIV-infected patients4
Statin use reduces markers of immune activation in HIV
positive cells without any effect on viral load.5
1. HIV Clin Trials. 2012 May-Jun;13(3):153-61
2. Moore RD, Bartlett JG, Gallant JE PLoS ONE:2011 vol:6 iss:7 pg:e21843 -e21843
3. J ClinLipidol. 2010 Jul-Aug;4(4):279-87.
4. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010; 30: 2611-2620
5. J Infect Dis. (2011) 203 (6): 756-764. doi: 10.1093/infdis/jiq115
34. Future Research
Does using Ace-Inhibitors and Angiotension Receptor
Blockers in HIV patients with early CAD improve
outcome ?
Will the use of lipid neutral and metabolic neutral ART
agents have significant impact on CVS outcomes ?
Will patients with erratic medication adherence have
poorer CVS outcomes on the long term ?
Does the practice on induction of virologic suppression
with high genetic barrier for resistance regimens with
switch to less metabolic and lipid neutral agents for
maintenance confer any long term benefit ?
Editor's Notes
This data represents a large European and North American Cohort of Patients. These are patients are individuals who initiated ART therapy from 1996 – 2006. Total of 39,272 patients from 13 different HIV positive Cohorts.
The relative risk calculated was after adjusting for age, gender, race, hypertension, diabetes, and dyslipidemia. There was no adjustment for smoking since the database had a lot of incomplete data on smoking.The risk associated with lipodystrophy and other HIV related body fat redistribution may be more significant in HIV positive women. ( J Acquir Immune DeficSyndr 2005; 39:44-54)
The case control study on MI incidences was from a Los Angeles Cedars-Sinai Medical Center. HIV patients have a higher incidence of recurrent coronary and atherothrombotic events (re-infarction or unstable angina) over a 15month follow up period. (Small study 24 HIV positive matched to 48 HIV negatives)Data from DAD Study Group from 1996 – 2001 from about 23, 437 patients median age 39yrs 34 – 45 IQR.Based on data from MediCal population 1994 - 2000 large study 3,083,209 individuals with 28,513 persons being HIV positive. Several limitations including lack of good data on smoking and family history to help adjust for these risk factors. There is an obvious likelihood of Medical Surveillance bias as HIV positive patients in care have more opportunities to have CHD diagnosed on account of them having more frequent visits.Danish Study included 4252 Residents of Denmark with a HIV diagnosis prior to January 2005; the Data was from the Danish HIV Cohort Study and 373, 856 controls. The Danish National Hospital Registry and the Danish Civil Registration System was the source of the controls. Mean CD4 count at treatment onset was 182 (74 – 290) IQR
The data for this table was derived from 5 different cohorts DAD study data from 2003 and 2006. Bozzette data is from the VA Cohort from 1993 - 2001 which is predominantly male and has limitations for generalizability. Klein used data from the Kaiser Permanente Database for his studies the 2002 paper was for data from January 1996 to June 2001. The second estimate was from 2001 – 2006 the late HAART period and was presented at CROI 2007. The Triant data was from the Mass General Hospital and Brigham and Women Hospital between Oct 1996 – June 2004. Currier et al used data from Medi-Cal ( The California Medicaid Claims database) data was drawn from claims with HIV specific ICD codes from July 1994 – June 2000.
This study by Currier J et all is based on a nested case control study from the Medi-Cal database and may not be very representative of the general population. Medicaid patients without HIV may on average by sicker, this may not apply to HIV patients who may have been enrolled in medicaid on account of their HIV status.
Low level viremia in the study of the Athena cohort patients was defined as 50 – 400, and high level viremia as viral load > 400 copies. The SMART study also produced overwhelming data in support of the fact that plasma viremia does have a deleterious effect on cardiovascular endpoints.
2. Paper presented at CROI 2012 a group from the French National Agency for Research on AIDS and Viral Hepatitis reported an association between vitamin D levels and CD4 counts < 100 cells. In this study the HIV positive patients with the lowest tertile of 25(OH) Vitamin D level had higher mean levels of inflammatory markers hsCRP (P = 0.047), sTNFR1 (P = 0.02). In subgroup analysis they found an association between vitamin D levels and insulin resistance in white patients this association was not found for black patients. The consisted of 355 treatment naïve patients, 204 white and 151 black mostly Africans from the continent, 30% of the patients where women. Another paper presented at CROI found a strong association between Vitamin D and adiponectin levels in HIV patients small study sample size 103. 3. A secondary data analysis of the FRAM (Fat Redistribution and Metabolic Changes in HIV Study and MESA (Multi-Ethnic Study of Atherosclerosis) shows a strong association between HIV and cIMT and HIV similar to the association between cIMT and smoking in men and 4x the association seen in smoking and cIMT in women.
The normal muscular artery and the cell changes that occur during disease progression to thrombosis are shown. a, The normal artery contains three layers. The inner layer, the tunica intima, is lined by a monolayer of endothelial cells that is in contact with blood overlying a basement membrane. In contrast to many animal species used for atherosclerosis experiments, the human intima contains resident smooth muscle cells (SMCs). The middle layer, or tunica media, contains SMCs embedded in a complex extracellular matrix. Arteries affected by obstructive atherosclerosis generally have the structure of muscular arteries. The arteries often studied in experimental atherosclerosis are elastic arteries, which have clearly demarcated laminae in the tunica media, where layers of elastin lie between strata of SMCs. The adventitia, the outer layer of arteries, contains mast cells, nerve endings and microvessels. b, The initial steps of atherosclerosis include adhesion of blood leukocytes to the activated endothelial monolayer, directed migration of the bound leukocytes into the intima, maturation of monocytes (the most numerous of the leukocytes recruited) into macrophages, and their uptake of lipid, yielding foam cells. c, Lesion progression involves the migration of SMCs from the media to the intima, the proliferation of resident intimalSMCs and media-derived SMCs, and the heightened synthesis of extracellular matrix macromolecules such as collagen, elastin and proteoglycans. Plaque macrophages and SMCs can die in advancing lesions, some by apoptosis. Extracellular lipid derived from dead and dying cells can accumulate in the central region of a plaque, often denoted the lipid or necrotic core. Advancing plaques also contain cholesterol crystals and microvessels. d, Thrombosis, the ultimate complication of atherosclerosis, often complicates a physical disruption of the atherosclerotic plaque. Shown is a fracture of the plaque's fibrous cap, which has enabled blood coagulation components to come into contact with tissue factors in the plaque's interior, triggering the thrombus that extends into the vessel lumen, where it can impede blood flow.
1. Compared corellation between Framingham Risk and Coronary Artery Calcium, Sample was 330 HIV positive patients 69.4% men. 2
5. Of 24 randomized participants, 22 completed the study. Although HIV-1 RNA level was unaffected by the intervention (–0.13 log10 copies/mL; P = .85), atorvastatin use resulted in reductions in circulating proportions of CD4+ HLA-DR+ (–2.5%; P = .02), CD8+ HLA-DR+ (–5%; P = .006), and CD8+ HLA-DR+ CD38+ T cells (–3%; P = .03).